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Background: This study investigated the effects of salmonella infection and its chemotherapy on lipid metabolism
in tissues of rats infected orally with Salmonella typhimurium and treated intraperitoneally with pefloxacin and
amoxillin.
Methods: Animals were infected with Salmonella enterica serovar Typhimurium strain TA 98. After salmonellosis was
confirmed, they were divided into 7 groups of 5 animals each. While one group served as infected control group, three
groups were treated with amoxillin (7.14 mg/kg body weight, 8 hourly) and the remaining three groups with
pefloxacin (5.71mg/kg body weight, 12 hourly) for 5 and 10 days respectively. Uninfected control animals received
0.1ml of vehicle. Rats were sacrificed 24h after 5 and 10 days of antibiotic treatment and 5 days after discontinuation of
antibiotic treatment. Their corresponding controls were also sacrificed at the same time point. Blood and tissue lipids
were then evaluated.
Results: Salmonella infection resulted in dyslipidemia characterised by increased concentrations of free fatty acids
(FFA) in plasma and erythrocyte, as well as enhanced cholesterogenesis, hypertriglyceridemia and phospholipidosis in
plasma, low density lipoprotein-very low density lipoprotein (LDL-VLDL), erythrocytes, erythrocyte ghost and the
organs. The antibiotics reversed the dyslipidemia but not totally. A significant correlation was observed between fecal
bacterial load and plasma cholesterol (r=0.456, p<0.01), plasma triacyglycerols (r=0.485, p<0.01), plasma phospholipid
(r=0.414, p<0.05), plasma free fatty acids (r=0.485, p<0.01), liver phospholipid (r=0.459, p<0.01) and brain phospholipid
(r=0.343, p<0.05).
Conclusion: The findings of this study suggest that salmonella infection in rats and its therapy with pefloxacin and
amoxillin perturb lipid metabolism and this perturbation is characterised by cholesterogenesis.
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Salmonella spp. are important aetiological agents of various
diseases resulting from feco-oral infection. A characteristic
feature of the organisms in the genus Salmonella is their
wide host range which comprises most animal species in-
cluding mammals, birds and cold-blooded animals [1].
There are two types of food-borne infections causing
serious medical and veterinary problems worldwide: i) in-
testinal or non-typhoid form (salmonellosis) caused by hun-
dreds of different serovariants of S. enterica, including
serovar Typhimurium and ii) generalized or typhoid form
(enteric fever) caused by S. enterica serovar Typhi.* Correspondence: adelad2@yahoo.com
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reproduction in any medium, provided the orEnterocolitis characteristic of non-typhoid forms is by
far the most common manifestation of salmonella-
derived infections in humans that under certain cir-
cumstances are accompanied by septicaemia [2,3],
causing the increase of mortality.
By two distinct mechanisms (via M cells or enterocytes)
S. typhi is believed to translocate rapidly and efficiently
from the lumen of the human intestine through the
mucosa to eventually reach the reticuloendothelial system
and gall bladder, where, following a relatively long incuba-
tion, they precipitate a systemic febrile illness accom-
panied by a low-level secondary bacteremia [1,4]
often resulting in sepsis [5-9].
The host metabolic response of the body following
sepsis comprises mobilization of substrates from theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cells [10], resulting in loss of lean body mass. Conse-
quently, gluconeogenic and other amino acids are
released in increased amounts into the circulation. The
glucose produced in this response is the main energy
source for cells involved in the host immune response
during sepsis [10]. In addition to accelerated gluconeo-
genesis, peripheral mobilized amino acids serve as
substrates for central organs, including liver (for acute-
phase protein (APR) synthesis) and enterocytes [11,12].
Although, changes in carbohydrate metabolism with
consecutive hyperglycemia and hyperlactatemia, and in
protein metabolism, which results in enhanced acute-
phase protein synthesis and tissue protein catabolism
with subsequent negative nitrogen balance have been
reported, there is a dearth of information on the lipid
metabolism in the tissues of the host.
As a result of these alterations and their consequence
on the host, the management of salmonellosis and/or
the resulting sepsis often involves supportive measures
as well as the use of antibiotics which are generally
employed as the first-line treatment [9,13,14]. Fluoroqui-
nolones (e.g. pefloxacin) are considered to be optimal
therapy while amoxillin is often used as alternative ef-
fective therapy [13-15]. Amoxillin is a β-lactam amino-
penicillin and acts by inhibiting the synthesis of bacterial
cell walls while pefloxacin as a fluoroquinolone blocks
bacterial DNA synthesis [1,2]. Despite the use of antibio-
tics, aggressive operative intervention, nutritional sup-
port, and even anticytokine therapies, multiple organ
failure continues to be a major cause of morbidity and
mortality in sepsis [1,15-17]. Thus, it is essential to study
the impact of chemotherapy on tissue lipid metabolism
in experimental salmonellosis.
Results
Table 1 summarises the effects of pefloxacin and amoxil-
lin on the fecal bacteria load and weight gain of the rats
infected with S. typhimurium. The oral infection of the
rats with S. typhimurium caused salmonellosis as
observed by the apperance of S. typhimurium in the
feaces of the rats. The concentration of S. typhimurium
cultured in the feaces was significantly (p<0.05)
decreased upon the administration of pefloxacin and
amoxillin for 5 days. The decrease was sustained even 5
days after discontinuing antibiotic administration. TheTable 1 Fecal bacteria load and weight gain of the animals
Normal
control
Infection
control
Infecte
pefloxa
day 5
Fecal bacteria load (log CFU/g feaces) 0.00±0.00a 4.34±0.01d 4.03±0.
Weight change (g) 32.80±4.41a −14.33±2.39d −1.00±1
Each value represents the mean±S.E.M of 5 rats. Values within the same row with dbody weight of the animals was significantly (p<0.05)
decreased in S. typhimurium infection. Although the
drugs reversed the weight loss, none was able to bring it
to control values.
In Table 2 is the summary of the effects of pefloxacin
and amoxillin on plasma, HDL and LDL-VLDL lipid
profiles of rats infected with S. typhimurium. Salmonel-
losis caused a double-fold increase in the plasma level of
cholesterol, triacylglycerols, phospholipid and free fatty
acids. The increase in cholesterol level was reversed by
treatment with pefloxacin and amoxillin for 5 days and
10 days. On day 15, only amoxillin had a further signifi-
cant (p<0.05) reduction; however, this was still signifi-
catly (p<0.05) higher than the cholesterol in the plasma
of the normal control. The increase in triacylglycerol
was reversed more by pefloxacin on day 5 and day 10
than amoxillin. This trend continued to day 15 with ani-
mals infected pefloxacin day 15 group having triacylgly-
cerol level not significantly (p>0.05) different from the
normal control. After 5 days of treating the infected ani-
mals, only pefloxacin significantly (p<0.05) reduced the
level of phospholipids in the plasma. However, upon
completion of the treatments on day 10, both pefloxacin
and amoxillin had produced a similar reduction of the
elevated plasma phospholipid level. Although, no further
reduction was observed in animals in infected pefloxacin
day 15 group, that of the infected animals treated with
amoxillin was reversed to a level not significantly
(p>0.05) different from the normal control on day 15.
Salmonellosis caused a significant (p<0.05) decrease in
the level of HDL cholesterol and HDL phospholipid
whereas no significant change was observed in the HDL
triacylglycerol level. Treatment with the antibiotics
reversed the trend observed in cholesterol and phospho-
lipid, although at 5 days post-treatment with amoxillin,
HDL phospholipid was about 71% of the control value.
Salmonellosis also resulted in a significant (p<0.05) in-
crease in the levels of cholesterol, triacylglycerols and
phospholipid in the LDL-VLDL fraction of the plasma.
Although the increase in the cholesterol and triacylgly-
cerols concentrations was reversed by pefloxacin and
amoxillin on day 5, a rebound to higher values was
observed on day 10 for both drugs. By day 15 however, a
significant drop was observed with values obtained for
both drugs being significantly higher than controls
(p<0.05) for phospholipid, however, the rebound tod+
cin
Infected+
pefloxacin
day 10
Infected +
pefloxacin
day 15
Infected+
amoxillin
day 5
Infected+
amoxillin
day 10
Infected +
amoxillin
day 15
01c 2.59±0.24b 2.31±0.09b 4.11±0.06c 2.99±0.08b 2.64±0.04b
.00c −4.00±4.15c −8.50±3.37c 0.00±1.67b −7.50±7.98c −2.50±1.80c
ifferent superscripts are significantly different at p<0.05.
Table 2 Plasma, HDL and LDL-VLDL lipid profile of the animals
Plasma Normal
control
Infection
control
Infected+
pefloxacin
day 5
Infected+
pefloxacin
day 10
Infected +
pefloxacin
day 15
Infected+
amoxillin
day 5
Infected+
amoxillin
day 10
Infected +
amoxillin
day 15
Cholesterol (mg/dl) 56.60±2.43a 104.13±6.60b 79.14±5.49c 79.04±5.84c 77.96±5.73c 59.86±7.54d 73.55±7.05c 69.16±6.70d
Triacylglycerols (mg/dl) 63.18±5.19a 125.18±14.26c 77.32±0.99b 97.48±10.89c 58.43±5.89a 112.78±6.78d 127.58±17.61d 68.16±3.72b
Phospholipid (mg/dl) 75.33±15.41a 129.60±23.13c 122.96±7.93c 100.60±15.55b 109.84±10.18b 130.25±18.29c 109.35±10.40b 66.10±20.74a
Free Fatty acid (mg/dl) 14.10±2.25a 23.08±0.75c 17.20±0.39b 16.50±1.23b 17.28±0.55b 17.70±1.18b 16.16±0.53b 18.87±0.74b
HDL
Cholesterol (mg/dl) 39.06±2.77b 22.19±0.94a 21.08±4.03a 37.19±8.41b 21.16±1.39a 18.06±5.97a 36.76±2.74b 22.36±1.75a
Triacylglycerols (mg/dl) 26.83±3.65a 37.75±7.17a 25.12±3.63a 33.98±3.43a 25.81±2.29a 28.26±5.51a 27.28±4.08a 39.50±4.14a
Phospholipid (mg/dl) 68.53±1.42a 29.57±1.71b 89.91±19.50e 73.87±12.24d 52.49±7.31c 71.93±7.31d 66.10±14.67d 48.60±7.37c
LDL-VLDL
Cholesterol (mg/dl) 25.94±2.31b 49.03±2.39e 15.24±2.32a 43.38±3.75e 36.17±3.23d 28.64±3.34c 43.38±3.00e 34.33±3.80d
Triacylglycerols (mg/dl) 22.43±1.72a 68.66±4.26d 24.02±1.40a 56.50±8.71c 36.90±1.58b 28.61±2.78a 49.05±3.57c 58.37±7.38d
Phospholipid (mg/dl) 86.99±2.81a 95.18±5.63c 64.64±4.04b 110.81±2.73c 107.41±2.14c 69.50±4.18b 117.13±9.23d 83.11±4.31a
Each value represents the mean±S.E.M of 5 rats. Values within the same row with different superscripts are significantly different at p<0.05.
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treated animals, whereas a decrease on day 15 was
observed in amoxillin-treated animals.
Table 3 summarises the effects of pefloxacin and
amoxillin on erythrocyte and erythrocyte ghost lipid pro-
files of rats infected with S. typhimurium. While Sal-
monellosis caused a significant (p<0.05) increase in the
erythrocyte cholesterol, phospholipid and free fatty acid
levels with a significant (p<0.05) decrease in triacylgly-
ceride level, the increase in the cholesterol concentration
in the erythrocyte was reversed by pefloxacin on day 5
while both drugs significantly (p<0.05) reduced it to a
level significantly (p<0.05) lower than the normal control
by day 10. On day 15, rats treated with amoxillin had a
significantly (p<0.05) increased cholesterol concentration
to a level higher than the infection control. There was a
further decrease in the level of erythrocyte triacylglycerols
on day 5 in the rats treated with both pefloxacin and
amoxillin. This was however reversed with amoxillin to aTable 3 Erythrocyte and erythrocyte ghost lipid profile of the
Erythrocyte Normal
control
Infection
control
Infected+
pefloxacin
day 5
Infe
pef
day
Cholesterol (mg/dl) 113.43±19.54a 127.20±11.52d 99.61±9.21b 65.3
Triacylglycerols (mg/dl) 38.16±1.76a 31.28±2.23b 21.92±2.69c 38.1
Phospholipid (mg/dl) 156.49±4.71a 180.63±22.36b 139.00±6.45a 166
Free Fatty acid (mg/dl) 26.56±2.31a 35.72±0.78b 29.80±0.39c 29.0
Erythrocyte ghost
Cholesterol (mg/g) 7.03±0.27a 10.61±0.90b 6.93±0.24a 6.60
Triacylglycerols (mg/g) 3.94±0.27a 6.84±0.68c 4.35±0.14a 2.81
Phospholipid (mg/g) 7.91±0.26a 20.10±2.68c 10.12±0.22b 9.11
Each value represents the mean±S.E.M of 5 rats. Values within the same row with dlevel not significantly (p>0.05) different from normal
control and by pefloxacin to a level significantly (p<0.05)
higher than normal control. Pefloxacin on day 5 and day
10 reversed the increase in the level of phospholipid in the
erythrocyte. Rats treated with amoxillin had their erythro-
cyte phospholipid level significantly (p<0.05) higher on
day 10 than normal control. Although both antibiotics
on day 5 and pefloxacin on day 10 reversed the
salmonellosis-induced increased free fatty acid, values
obtained were still significantly higher than normal
control. Values obtained with amoxillin on day 10
and pefloxacin on day 15 were not significantly
(p>0.05) different from normal control.
The infection of the rats by S. typhimurium was asso-
ciated with a significant (p<0.05) increase in erythrocyte
ghost cholesterol, triacylglycerols and phospholipid
concentrations. The increase in cholesterol amounted to
51% whereas increase in triacylglycerol and phospholi-
pids amounted to 74% and 154% respectively. Foranimals
cted+
loxacin
10
Infected +
pefloxacin
day 15
Infected+
amoxillin
day 5
Infected+
amoxillin
day 10
Infected +
amoxillin
day 15
9±2.62c 81.67±5.35b 124.96±16.23d 90.52±19.80b 156.33±13.04e
7±3.08a 39.37±1.76a 29.09±2.39b 46.05±3.81d 43.51±2.72e
.21±11.64a 113.72±8.77c 173.99±4.61b 179.82±5.45b 133.16±25.93a
6±1.25c 24.88±5.48a 30.30±1.14c 23.28±5.01a 31.48±7.36c
±0.41a 6.45±0.33a 6.06±1.65a 6.18±0.34a 7.79±1.26a
±0.29a 4.29±0.30a 4.21±1.20a 3.87±0.21a 5.15±0.82b
±1.05b 13.43±0.69b 12.63±4.30b 12.08±0.68b 15.86±2.73d
ifferent superscripts are significantly different at p<0.05.
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day 5 of treatment to a level not significantly (p>0.05)
different from the normal control and the reversal was
maintained through day 15. The response of triacygly-
cerol was also similar except for amoxillin on day 15
where the value obtained was higher than normal con-
trol but lower than the infection control. Although, there
was a significant reversal of the elevated level of
phospholipid by the chemotherapy, the levels produced
by the treatments were still significantly (p<0.05) higher
than the normal control.
Table 4 shows the effects of pefloxacin and amoxillin
on cholesterol:phospholipid ratios in the plasma, HDL,
LDL-VLDL, erythrocyte and erythrocyte ghost of rats
infected with S. typhimurium. The infection of rats with
S. typhimurium was associted with a significant (p<0.05)
increase in the cholesterol:phospholipid ratios in the
plasma, HDL, LDL-VLDL and erythrocyte ghost. The
elevation of this ratio in the plasma was reversed in all
the groups except infected+amoxicillin day 15. Similar
reversals were observed in HDL and LDL-VLDL when
compared with the infection control. Except for pefloxa-
cin on day 10, amoxillin on days 10 and 15, the elevation
of this ratio in the erythrocyte was not significantly
(p>0.05) altered by any of the treatments.
The effects of pefloxacin and amoxillin on atherogenic
index of rats infected with S. typhimurium is depicted in
Figure 1. Salmonellosis caused a 3 fold increase in this
index. This was reduced by both pefloxacin and amoxillin
after 10 days of treatment and this reversal was maintained
by both drugs through day 15.
The summary of the effects of pefloxacin and amoxi-
cillin on the lipid profiles of organs of rats infected with
S. typhimurium is shown in Table 5. Salmonellosis
caused a significant (p<0.05) increase in the levels of
cholesterol and triacylglycerols in all the organs. How-
ever, phospholipid concentration was significantly
(p<0.05) increased in the liver, kidney and brain alone
with spleen and heart having decreased levels. In the
liver, treatment with pefloxacin and amoxillin for 5 and
10 days caused a further significant (p<0.05) increase in
cholesterol level. However, this increase was reversed inTable 4 Cholesterol: Phospholipid ratios in the plasma, HDL,
animals
Normal control Infection control Infected+
pefloxacin
day 5
Plasma 0.87±0.16a 1.02±0.34b 0.69±0.10a
HDL 0.57±0.04a 0.79±0.03d 0.38±0.09b
LDL-VLDL 0.30±0.03a 0.51±0.06c 0.31±0.09a
Erythrocyte 0.78±0.10a 0.71±0.12a 0.77±0.08a
Erythrocyte ghost 0.89±0.04a 0.54±0.07b 0.68±0.02b
Each value represents the mean ± S.E.M of 5 rats. Values within the same row withpefloxacin treated group on day 15. While the increase
in hepatic triacylglycerols by both antibiotics was
reversed on day 15, that of hepatic phosphoslipid was
not significantly altered.
In the kidney, treatment with pefloxacin resulted in a
significant (p<0.05) decrease in cholesterol concentration
from day 5 while amoxillin caused a further significant
(p<0.05) increase. Although the increase in triacyglycerol
was decreased on day 15 in infected rats treated with
both antibiotics, their levels were still significantly
(p<0.05) higher than that of the normal control. The
phospholipid levels in infected rats treated with pefloxa-
cin and amoxillin was still significantly (p<0.05) high on
day 10; however, there was a significant (p<0.05) and
complete reversal on day 15.
The decrease in the level of brain cholesterol after 5
days of pefloxacin and amoxillin administration was
reversed on days 10 and 15. Both antibiotics caused
further increase in the brain triacylglycerols after 5 days
of administration with amoxillin treatment giving a re-
versal on days 10 and 15. Pefloxacin administration
caused a further significant (p<0.05) increase in brain
phospholipid level on day 15 alone while amoxillin therapy
caused a significant (p<0.05) increase on day 5. However,
this was reversed on day 10.
In the spleen, treatment of salmonellosis with pefloxa-
cin caused a significant (p<0.05) decrease in cholesterol
and triacyglycerol levels. As treatment continued however,
there was a rebound to higher values in both cholesterol
and triacyglycerol. The salmonellosis-induced decrease in
the spleen phospholipid was reversed by both drugs on
day 5 and by day 15 amoxillin-treated rats had phospho-
lipid concentration not significantly (p>0.05) different
from that of the normal control.
Salmonellosis-induced cardiac hypercholesterolemia
was reversed after 10 days of treatment with both anti-
biotics. Both antibiotics caused a further significant
(p<0.05) increase in heart phospholipid level from day 5
through day 15 except amoxillin day 10 which was not
significantly (p>0.05) different from the normal control.
Table 6 shows the summary of the effects of pefloxacin
and amoxillin on the cholesterol:phospholipid ratios inLDL-VLDL, erythrocyte and erythrocyte ghost of the
Infected+
pefloxacin
day 10
Infected +
pefloxacin
day 15
Infected+
amoxillin
day 5
Infected+
amoxillin
day 10
Infected +
amoxillin
day 15
0.87±0.15a 0.72±0.04a 0.56±0.11a 0.70±0.10a 1.62±0.60c
0.52±0.12c 0.43±0.06b 0.25±0.07b 0.66±0.14c 0.50±0.07c
0.42±0.07b 0.36±0.05b 0.41±0.06b 0.38±0.040b 0.41±0.03b
0.39±0.02b 0.74±0.07a 0.75±0.15a 0.49±0.08b 1.53±0.50c
0.52±0.02b 0.48±0.01b 0.53±0.04b 0.51±0.02b 0.49±0.01b
different superscripts are significantly different at p<0.05.
Figure 1 Atherogenic indices of the animals. Each bar represents the mean ± S.E.M of 5 rats. Bars with different alphabets are significantly
different at p<0.05.
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ellosis caused a significant (p<0.05) decrease in this ratio
in liver and kidney with a significant (p<0.05) increase in
brain, spleen and heart. The decrease in the liver and
kidney was reversed after treatment with both antibio-
tics. Both drugs only caused a significant (p<0.05)Table 5 Lipid profiles of liver, kidney, brain, spleen and heart
Liver Normal control Infection control Infected+
pefloxacin
day 5
Cholesterol (mg/g) 2.34±0.07a 2.57±0.03b 2.88±0.12c
Triacylglycerols (mg/g) 1.56±0.19b 1.97±0.13d 2.39±0.08e
Phospholipid (mg/g) 14.29±0.95a 27.30±0.92c 24.79±1.93b
Kidney
Cholesterol (mg/g) 2.58±0.35a 3.05±0.25b 2.48±0.38a
Triacylglycerols (mg/g) 4.25±0.29a 9.35±0.31c 9.92±0.50c
Phospholipid (mg/g) 10.01±0.79a 18.79±0.57d 11.57±0.85a
Brain
Cholesterol (mg/g) 12.24±0.59a 19.72±1.23c 10.70±0.68a
Triacylglycerols (mg/g) 0.60±0.06a 1.96±0.03c 1.97±0.03c
Phospholipid (mg/g) 39.46±2.00a 49.17±2.28b 47.43±1.97b
Spleen
Cholesterol (mg/g) 1.09±0.11a 1.63±0.23b 1.47±0.23c
Triacylglycerols (mg/g) 0.56±0.16a 1.50±0.07b 1.00±0.20b
Phospholipid (mg/g) 12.49±1.35a 8.55±0.53a 9.28±0.98d
Heart
Cholesterol (mg/g) 0.58±0.05a 0.82±0.04c 0.82±0.04c
Triacylglycerols (mg/g) 2.81±0.48a 4.63±0.34a 4.02±0.43a
Phospholipid (mg/g) 10.35±0.46a 7.45±1.00b 8.12±1.10c
Each value represents the mean±S.E.M of 5 rats. Values within the same row with ddecrease of the elevated cholesterol:phospholipid ratio in
brain on day 5 of the treatment. In the spleen, the values
of this ratio in all the treatments were not significantly
(p>0.05) different from the infection control except
infected+amoxicillin day 10 which was significantly
(p<0.05) lower than the infection control. On day 10 ofof the animals
Infected+
pefloxacin
day 10
Infected +
pefloxacin
day 15
Infected+
amoxillin
day 5
Infected+
amoxillin
day 10
Infected +
amoxillin
day 15
2.62±0.08d 2.33±0.06a 2.71±0.12d 2.64±0.10d 2.72±0.08d
1.85±0.14c 1.22±0.07a 2.32±0.08e 2.22±0.07e 1.66±0.08c
26.15±3.82b 21.00±0.93b 25.17±1.69b 21.48±1.48b 23.72±1.31b
2.60±0.30a 2.44±0.32a 3.25±0.14b 4.33±0.62c 3.09±0.75b
12.24±0.57d 6.99±0.44b 6.23±1.03b 12.24±0.76d 6.71±0.67b
15.94±1.21cd 9.14±0.32a 12.25±1.08a 13.02±1.71b 9.72±1.12a
16.05±0.86b 19.90±1.01c 16.29±1.28b 17.12±0.95e 16.72±1.43e
2.10±0.12e 2.08±0.05e 2.22±0.05d 1.91±0.04f 1.88±0.07b
42.38±2.03b 54.04±2.86c 52.59±3.80c 39.95±2.46a 38.01±4.63a
2.21±0.26e 2.12±0.06e 2.02±0.13d 1.43±0.33c 2.19±0.34e
1.04±0.18b 1.26±0.24b 1.57±0.32b 1.58±0.60b 1.96±0.50c
10.69±1.11b 8.41±0.37c 11.37±0.48e 9.23±0.47d 11.86±0.48a
0.53±0.02a 0.41±0.01b 0.72±0.06c 0.41±0.02b 0.46±0.05b
4.04±0.75a 3.86±0.87a 4.71±1.17a 4.22±0.78a 3.51±0.69a
8.94±0.80c 7.82±0.52c 7.82±0.65c 7.53±0.43b 8.99±0.84b
ifferent superscripts are significantly different at p<0.05.
Table 6 Cholesterol: Phospholipid ratios in the organs of the animals
Normal control Infection control Infected+
pefloxacin
day 5
Infected+
pefloxacin
day 10
Infected +
pefloxacin
day 15
Infected+
amoxillin
day 5
Infected+
amoxillin
day 10
Infected +
amoxillin
day 15
Liver 0.17±0.01a 0.09±0.01c 0.12±0.01b 0.11±0.02b 0.11±0.01b 0.110±0.01b 0.13±0.01b 0.12±0.01b
Kidney 0.28±0.06a 0.16±0.02b 0.21±0.04a 0.19±0.04a 0.27±0.04c 0.259±0.02a 0.34±0.04c 0.31±0.06c
Brain 0.31±0.02a 0.40±0.02b 0.26±0.04c 0.38±0.01b 0.37±0.02a 0.313±0.01c 0.43±0.02d 0.46±0.07d
Spleen 0.09±0.02a 0.18±0.03b 0.18±0.03b 0.21±0.02b 0.25±0.01b 0.175±0.01b 0.16±0.04c 0.19±0.03b
Heart 0.06±0.01a 0.12±0.02b 0.12±0.02b 0.06±0.01a 0.05±0.01c 0.095±0.01b 0.06±0.01a 0.05±0.01a
Each value represents the mean±S.E.M of 5 rats. Values within the same row with different superscripts are significantly different at p<0.05.
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in the heart was reversed to a level not significantly
(p>0.05) different from the normal control.
Figure 2 depicts the effects of salmonellosis and its
chemotherapy with pefloxacin and amoxillin on hepatic
HMG-CoA/mevalonate ratios as an index of the activity
of HMG-CoA reductase. Salmonellosis caused a 3.5 fold
decrease in this ratio. Both antibiotics reversed this
trend. The reversal by pefloxacin was however more
pronounced than that of amoxillin. Five days after the
withdrawal of both antibiotics, activity of HMG-CoA
reductase had not returned to control values.
Intensity of associations between fecal bacteria load
and lipid profiles and hepatic HMG-CoA/Mevalonate
ratio in rats infected with S. typhimurium is shown in
Table 7. The fecal bacteria load was positively correlated
with plasma cholesterol (r=0.456, p<0.01), plasma tria-
cylglycerols (r=0.485, p<0.01), plasma phospholipid
(r=0.414, p<0.01), plasma free fatty acid (r=0.485,
p<0.01), LDL-VLDL triacylglycerols (r=0.313, p<0.05),
liver cholesterol (r= 0.464, p<0.01), liver triacylglycerols
(r= 0.546, p<0.01), liver phospholipid (r= 0.680, p<0.01),
kidney triacylglycerols (r=0.445, p<0.01), kidney phospho-
lipid (r= 0.459, p<0.01), brain triacylglycerols (r=0.785,Figure 2 Hepatic HMG CoA/Mevanolate ratios of the animals. NB: This
represents the mean±S.E.M of 5rats. Bars with different alphabets are signifp<0.01), brain phospholipid (r= 0.343, p<0.05), heart chol-
esterol (r= 0.488, p<0.01) and erythrocyte ghost phospho-
lipid (r=0.359, p<0.05). A negative association was
however observed with HDL cholesterol (r= −0.485,
p<0.01), erythrocyte triacylglycerols (r= −0.318, p<0.05),
spleen phospholipid (r= −0.419, p<0.01), heart phospho-
lipid (r= −0.415, p<0.01) and hepatic HMG CoA/Mevalo-
nate ratio (r= −0.501, p<0.01).
Discussion
The results of this study indicate that fecal excretion of
salmonella and weight loss are associated with sal-
monella infection and that antibiotics may not
completely eradicate salmonella from the colon. Our
results are consistent with other studies that have
reported colonisation of both the ileum and colon by
the microbe and subsequent fecal excretion for
several weeks [18]. Weight loss in salmonella infec-
tion, attributed to diarrhea, decrease in appetite and
general inflammation of the gastrointestinal tract,
have also been reported [18,19].
A major finding of this study was that Salmonellosis
perturbs the metabolism of lipids in different compart-
ments of the animals. These perturbations were reflectedratio is used as an index of HMG CoA reductase activity. Each bar
icantly different at p<0.05.
Table 7 Intensity of association between fecal bacteria
load and lipid profiles and hepatic HMG CoA/Mevalonate
ratio in the animals
Parameters Correlation
coefficient
Fecal Bacteria load vs. Weight change −0.609a
Fecal Bacteria load vs. Plasma Cholesterol 0.456a
Fecal Bacteria load vs. Plasma Triacylglycerols 0.485a
Fecal Bacteria load vs. Plasma Phospholipid 0.414a
Fecal Bacteria load vs. Plasma free fatty acids 0.485a
Fecal Bacteria load vs. HDL Cholesterol −0.485a
Fecal Bacteria load vs. LDL-VLDL Triacylglycerols 0.313b
Fecal Bacteria load vs. Erythrocyte
Triacylglycerols
−0.318b
Fecal Bacteria load vs. Liver Cholesterol 0.464a
Fecal Bacteria load vs. Liver Triacylglycerols 0.546a
Fecal Bacteria load vs. Liver Phospholipid 0.680a
Fecal Bacteria load vs. Kidney Triacylglycerols 0.445a
Fecal Bacteria load vs. Kidney Phospholipid 0.459a
Fecal Bacteria load vs. Brain Triacylglycerols 0.785a
Fecal Bacteria load vs. Brain Phospholipid 0.343b
Fecal Bacteria load vs. Spleen Phospholipid −0.419a
Fecal Bacteria load vs. Heart Cholesterol 0.488a
Fecal Bacteria load vs. Heart Phospholipid −0.415a
Fecal Bacteria load vs. Erythrocyte ghost
Phospholipid
0.359b
Fecal Bacteria load vs. HMG CoA/Mevalonate −0.501a
a Correlation is significant at p< 0.01.
b Correlation is significant at p< 0.05.
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major lipids (cholesterol, triacylglycerols, phospholipids
and free fatty acids). The data also indicate that the ac-
tivity of hepatic HMG-CoA reductase was up-regulated
as a result of salmonellosis and its chemotherapy. During
infection, a wide range of alterations in metabolism occur.
These are part of the body’s reactions which help protect
the host from further injury, and facilitates the repair
process [20]. However, these metabolic changes, if
present for prolonged periods, can lead to detrimental
consequences on the host.
The increased triacylglycerol levels as well as increase
in VLDL and reduced HDL cholesterol levels observed
in this study are characteristic changes that have been
reported to occur during infection [21,22]. The conse-
quence of this type of change is promotion of athero-
genesis as observed by increased atherogenic index of
the animals. Elevation of plasma triacylglycerol level could
be the result of either increased VLDL production or
decreased VLDL clearance [23,24]. Experiments in rats
and mice showed that even at low doses, bacteria LPS can
rapidly stimulate VLDL production by increasing adiposetissue lipolysis, increasing hepatic de novo fatty acid syn-
thesis, and decreasing hepatic fatty acid oxidation, all of
which provide fatty acid substrate for esterification into
triacylglycerols and assembly into VLDL particles in the
liver [24-27]. Injection of bacteria or LPS into rats had
been reported to significantly inhibit the clearance of
LDL from the circulation [28] and markedly increase
VLDL-triacylglycerol [29,30]. This mechanism may
also have been responsible for the increased plasma and
erythrocyte free fatty acids observed in the experimental
rats infected with Salmonella as the increase in free fatty
acids was associated with increased LDL-VLDL and
plasma triacylglycerols.
The findings of this study showed a salmonellosis-
induced hypercholesterolemia in the tissues of the
experimental animals. This enhanced cholesterogenesis
in the liver and brain of the animals may be attributed
to salmonella-induced activation of HMG-CoA (the
rate-limiting enzyme in cholesterol synthesis), while the
accumulation of cholesterol by other extra-hepatic tis-
sues may be mediated by an enhanced cholesterol efflux
from the liver since most extra-hepatic tissues obtain
their cholesterol from the liver [31]. This also suggests
inhibition of the enzyme cholesterol-7α-hydroxylase, the
rate-limiting enzyme in the conversion of cholesterol to
bile acids (a well known mechanism for the excretion of
cholesterol from the body) [32].
Another mechanism of cholesterol removal from the tis-
sues (most especially extra-hepatic tissues), is the
apolipoprotein-mediated cholesterol removal. An impair-
ment of this process is usually indicated by decreased
HDL cholesterol level [33] as observed in this study. HDL
and apolipoprotein (apo) A-I have been reported to be
receptors of cellular cholesterol [33]. In addition,
phospholipid transfer protein mediates a transfer of phos-
pholipids and cholesterol between triacylglycerols-rich
lipoproteins and HDL, and a reduction in phospholipid
transfer protein activity results in lower HDL levels [33].
Therefore, a reduction in phospholipid transfer protein ac-
tivity could presumably decrease cellular cholesterol
removal as well. Other factors that influence the level of
tissue cholesterol are the activities of plasma lecithin:-
cholesterol acyltransferase (LCAT) and cholesterol ester
transfer protein (CETP) [34]. While LCAT is required for
the conversion of free cholesterol into cholesterol ester so
that it can then move into the core of HDL, CETP med-
iates the exchange of cholesterol ester in HDL for triacyl-
glycerols in triacylglycerol-rich lipoproteins, an important
step in the delivery of cholesterol to the liver from extra-
hepatic tissues [34]. Although the activities of the two
enzymes were not determined in this study, reductions in
their activities which have been reported during infection
in other studies [35,36] could retard the reverse cholesterol
pathway as observed in this study.
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salmonellosis-induced phospholipidosis in the experi-
mental animals. The induction of phospholipidosis is
often characterized by: (1) inhibition of lysosomal
phospholipase activity—this is generally regarded as the
primary mechanism of induction, (2) inhibition of lyso-
somal enzyme transport as a result of down-regulation
of genes involved in lysosomal enzyme transport, (3)
enhanced phospholipid biosynthesis due to enhanced
free fatty acid availability and (4) enhanced cholestero-
genesis [37]. The data from this study indicate that the
latter two mechanisms might be involved in the induc-
tion of phospholipidosis. Previous studies have shown
that an infusion of a phospholipid-rich lipid emulsion
improved survival in a porcine model of septic peritonitis
[29,30], hence plasma, erythrocyte and tissue phospholipi-
dosis observed in this study might possibly be part of the
host response to salmonellosis. The ability of oxidized
phospholipids to modulate the LPS signaling is known to
be beneficial to the host during infection. In fact, oxi-
dized phospholipids have been shown to decrease in-
flammatory process in mice treated with LPS,
protecting them from endotoxic shock [36]. This may
explain why treatment with the antibiotics was unable
to reverse phospholipidosis as these antibiotics are
known to cause the release of LPS from the bacteria
cells into circulation [36].
Conclusion
Results of the present study provide evidence that dysli-
pidemia during and after administration of both amoxi-
liin and pefloxacin does occur in rat model of
salmonellosis. If these metabolic changes are present for
prolonged periods, they could be early signs in the
pathophysiology of atherosclerosis.
Methods
Chemicals
Pefloxacin was a product of Lek Pharmaceutical and
Chemical Company, Ljubljana, Slovenia, while amoxillin
was obtained from Beecham Pharmaceuticals, Brentford,
England. All other chemicals used in this study were of
the purest grade available and were obtained from
British Drug House (BDH) Chemicals Limited, Poole,
England and Sigma-Aldrich, Missouri, U. S. A.
Bacteria strain
Salmonella enterica serovar Typhimurium strain TA98
(obtained from the Nigerian Institute of Medical Research
(NIMR), Yaba, Lagos, Nigeria) was grown for 48 h under
static conditions in nutrient broth (CMI, Unipath, UK).
The organism was maintained on nutrient agar slant at
4°C. Bacteria were harvested from the slant, suspended
in 100ml nutrient broth and allowed to grow at 37°C for12 h (late logarithmic growth phase). The cells were spun
at 4,300 × g at 4°C for 10 min. Once the supernatant was
discarded, the cells were resuspended in 20 ml of buffer
and the centrifugation was repeated. The final washed pel-
let of bacteria cells was resuspended in 10 ml of
phosphate-buffered saline (PBS) pH 7.4. The stock con-
centration of bacteria was determined from an optical
density curve with a spectrophotometer.
Animal handling and experimental protocol
Experimental protocols were conducted in accord with
guidelines of the Institutional Animal Care and Use
Committee and were approved by the Animal Ethical
Committee of the Department of Biochemistry, University
of Agriculture Abeokuta. Pathogen free male albino rats
weighing 230-280 g obtained from the NIMR were used
for the study. The rats were housed in metabolic cages at
room temperature (22-24°C) and had free access to rat
chow and autoclaved tap water throughout the period of
the experiment. Animals were acclimatized to the housing
and dietary conditions for 2 weeks after which they were
fasted overnight and infected orally with 0.2 ml phosphate-
buffered saline (PBS) pH 7.4 containing 1 × 1010
colony-forming unit (CFU) live culture of the bacteria
as described Hung and Wang [38]. Twenty animals
that were not infected and received 0.2 ml PBS orally
served as the normal control.
In previous Salmonella infection studies in rats [18,21]
it was established that monitoring functional infection
outcomes like Salmonella colonisation, translocation
and infection induced changes, follow-up of infected rats
for at least 3 to 4 days is needed. Therefore the infected
rats were left for four days after which fresh faecal sam-
ples were collected to quantify Salmonella colonisation
daily, as described by van Ampting [39].
After salmonellosis was confirmed, infected animals
were divided into 7 groups of 5 animals each. While 1
group served as infection control group and sacrificed
immediately to obtain baseline values in salmonellosis
(Infection Control), three groups were treated with
amoxillin (7.14 mg/kg body weight, 8 hourly) and the
remaining three groups with pefloxacin (5.71 mg/kg
body weight, 12 hourly) for 5 and 10 days respectively.
The antibiotics were constituted in 5% dextrose and
were prepared fresh before each administration. They
were administered in a total volume of 0.1ml. Control
animals received equivalent volume of 5% dextrose. All
drug administration was by the intraperitoneal route.
Table 8 summarises the study protocol.
Twenty four hours after 5 and 10 days antibiotic treat-
ment and 5 days after the discontinuation of the antibio-
tics, blood was collected from the animals into
heparinised tubes by cardiac puncture under light ether
anaesthesia after an overnight fast. Their corresponding
Table 8 Study protocol
Treatment Group Treatment
Control Group 1 Control animals sacrificed when treatment of salmonella-infected animals with antibiotics commenced
(Designated as Normal Control in Tables)
Control Group 2 Control animals for 5 days of antibiotic treatment
Control Group 3 Control animals for 10 days of antibiotic treatment
Control Group 4 Control animals for day 15 (5 days after discontinuation of antibiotic treatment)
Salmonella group 5 Infected animals sacrificed when treatment with antibiotics commenced (Designated in Tables as Infection Control)
Salmonella group 6 Infected animals treated with amoxillin for 5 days and sacrificed 24h after amoxillin treatment (Designated in Tables as
Infected+Amoxillin day 5)
Salmonella group 7 Infected animals treated with amoxillin for 10 days and sacrificed 24h after amoxillin treatment (Designated in Tables as
Infected+Amoxillin day 10)
Salmonella group 8 Infected animals treated with amoxillin for 10 days and left for another 5 days to recover from antibiotic treatment before being
sacrificed (Designated in Tables as Infected+Amoxillin day 15)
Salmonella group 9 Infected animals treated with pefloxacin for 5 days and sacrificed 24h after pefloxacin treatment (Designated in Tables as
Infected+Pefloxacin day 5)
Salmonella group 10 Infected animals treated with pefloxacin for 10 days and sacrificed 24h after pefloxacin treatment (Designated in Tables as
Infected+Pefloxacin day 10)
Salmonella group 11 Infected animals treated with pefloxacin for 10 days and left for another 5 days to recover from antibiotic treatment before
being sacrificed (Designated in Tables as Infected+Pefloxacin day 15)
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Liver, kidney, brain, heart and spleen were removed from
the animals for biochemical analyses. Blood samples
were centrifuged to separate plasma and red blood cells.
All samples were stored at −20°C until analysed. Since
the values for many of these parameters in control ani-
mals did not change appreciably during the course of
the study, only values for one group of ‘Normal Control’
are presented in the tables.
Biochemical analyses
Plasma lipid profiles
Plasma concentrations of total cholesterol and triglycer-
ides were determined with commercial kits (Spin React
S.A., Santa Colona, Sant Esteve De Bas, Spain). HDL
cholesterol and triglycerides were determined in plasma
with same commercial kits for total cholesterol and tri-
glycerides after very low density lipoproteins (VLDL)
and LDL were precipitated with heparin-MnCl2 solution
[40]. Total phospholipids in plasma were extracted with
chloroform-methanol mixture (2:1, v/v) as described
by Folch et al. [41]. Phospholipid content was then
determined as described by Stewart [42]. Briefly, an
aliquot of the phospholipid extract was evaporated to
dryness at 60°C. After cooling, 2 ml of chloroform
was added to the dried lipid extract and vortexed.
Ammonium ferrothiocyanate (2 ml) was then added
and the mixture vortexed for 1 min. They were left
for 10 min for the phases to separate. The chloroform
layer was taken and absorbance read at 488 nm. Phospho-
lipid concentrations were then determined using a
phospholipid standard as reference.Atherogenic Index (AI) was calculated as the base 10
logarithm of the ratio of the concentration of triacygly-
cerol to high density lipoprotein cholesterol, where each
concentration is expressed in mmol/L [43].
Free fatty acids (FFA) in plasma were determined
according to the method of Soloni and Sardina [44] as
modified by Brunk and Swanson [45]. Briefly, to 100 μl
of plasma was added 300 μl of copper reagent and 2 ml
of chloroform. This was shaken with a vertical shaker
for 10 min and centrifuged. After centrifugation, the
chloroform layer was removed and to this was added
1 ml of cuprizone and 100 μl of ammonia reagent. The
contents were shaken briefly by hand and absorbance
read at 620 nm 10 min after adding ammonia reagent. A
standard curve of palmitic acid taken through the same
procedure was used to calculate the concentrations of
FFA in the plasma samples.
Erythrocyte lipid profile
Because the Folch extraction [41] produced lipid extracts
which were highly pigmented, an improved procedure
for the extraction of lipids from erythrocytes using
chloroform-isopropanol (7:11, v/v) described by Rose
and Oklander [46] was employed. For the determination
of cholesterol, an aliquot of the chloroform-isopropanol ex-
tract was evaporated to dryness at 60°C. Triton X-100/
chloroform mixture (1:1, v/v, 20 μl) was added to resolve
the lipids and again the solvent was evaporated. Then 1 ml
of commercially available cholesterol kit reagent (Spin
React S.A., Santa Colona, Sant Esteve De Bas, Spain) was
added and vortexed. After incubation in the dark at room
temperature for 30 min, cholesterol content was
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total phospholipids and free fatty acids in the chloroform-
isopropanol extract of the erythrocyte followed the same
procedure as described for plasma [42].
Organ lipid profiles
Lipids were extracted from the organs (liver, kidney,
brain, heart and spleen) as described by Folch et al.
(1957). After washing with 0.05M KCl solution, aliquots
of the chloroform-methanol extract were then used for
the determination of cholesterol, triglycerides and phos-
pholipids concentrations. Cholesterol was determined in
an aliquot of the chloroform-methanol extract of each
organ as described for erythrocytes while determination
of phospholipids followed the same procedure as
described for plasma. Triglyceride concentrations in ali-
quots of the chloroform-methanol extracts of each organ
were determined following the procedure described by
Kriketos et al. [48]. Briefly, an aliquot of the chloroform-
methanol extract in Eppendorf tubes was evaporated to
dryness at 60°C. After cooling, 200 μl of ethanol (97%)
was added to the tube to resuspend the triglyceride.
Then 1 ml of commercially available triglyceride kit
(Spin React S. A., Santa Colona, Sant Esteve De Bas,
Spain) was added and vortexed. After incubating in the
dark at room temperature for 20 min, triglyceride con-
tent was determined spectrophotometrically.
Isolation of erythrocyte ghost and determination of its
lipid profile
Erythrocyte membranes were prepared according to the
method described by Hanahan and Ekholm [49]. Briefly,
blood samples were centrifuged at 5000 rpm for 15 min
at 4°C. Plasma and buffy coat were removed by careful
suction and the cells were resuspended in isotonic Tris–
HCl buffer. After mixing by inversion, the samples were
recentrifuged at 5000 rpm for 15 min at 4°C. The super-
natant was again removed by careful suction and a few
red cells were sacrificed to remove any remaining buffy
layer. This washing procedure was repeated twice. The
washed cells were then suspended in isotonic Tris–HCl
buffer pH 7.6 to an approximate hematocrit of 50% and
were kept on ice. The samples were mixed gently by in-
version for about 1 min before membrane preparation.
5ml aliquots of the 50% cell suspensions were trans-
ferred to 50 ml polyethylene tubes. Thirty ml of hypo-
tonic Tris–HCl buffer pH 7.6 were added to the cell
suspension for osmotic lysis. After allowing the tubes to
stand for about 10 min, they were centrifuged at 20,000
rpm for 20 min at 4°C. The supernatants were discarded
and the pellets resuspended in 10 ml Tris–HCl and cen-
trifuged for 20 min at 20,000 rpm at 4°C. The pellets
were washed four times until the membranes were
colourless. Finally, the resultant pellets were rinsed twicewith 100 μl cold Tris–HCl buffer and poured into
Eppendorf tubes. The membrane suspensions were kept
frozen in this latter buffer at −20°C. Lipids were extracted
from the membrane suspensions and determined as
described for erythrocytes.
Determination of hepatic HMG-CoA reductase activity
This was determined according to the method of Rao and
Ramakrishnan [50]. Briefly, fresh liver homogenates were
mixed with equal volumes of perchloric acid. The mixture
was subsequently centrifuged (2,000 rpm for 10 min) and
the supernatant was treated with freshly prepared 1M
hydroxylamine in 2.25M NaOH. HMG-Co A was deter-
mined by subsequent colorimetric measurement of the
resulting hydroxamic acid by formation of complexes with
ferric salts at 540 nm. Mevalonate was estimated by reac-
tion with 1M hydroxylamine in water to form the hydroxa-
mate. The ratio of HMG-CoA to mevalonate is taken as an
index of the activity of HMG-CoA reductase. An increase
in this ratio indicates inhibition of cholesterogenesis while
a decrease indicates enhanced cholesterogenesis.
Statistical analysis
Data are expressed as mean ± S.E.M. One way analysis
of variance (ANOVA) followed by Duncan Multiple
Range Test was used to analyse the results with p < 0.05
considered significant.
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